- Oops!Something went wrong.Please try again later.
By Sam Boughedda
Investing.com — Aptevo Therapeutics Inc (NASDAQ:APVO) shares have surged over 129% to $14.88 Tuesday after it reported that a patient in its phase 1b expansion trial evaluating its treatment for acute myeloid leukemia had a complete remission.
The biotechnology explained that the high-risk AML patient achieved complete remission after one cycle of therapy. In addition, there was no evidence of overt toxicity, Aptevo said.
The overall aim of the study is to determine if the treatment can enhance the quality of remission in high-risk AML patients.
The company said it "believes that APVO436 has the potential to help AML patients achieve complete remissions without measurable residual disease (MRD) and thereby reduce their risk of leukemic relapses."